Pharmaids Pharmaceuticals Limited (BOM:524572)
India
· Delayed Price · Currency is INR 35.41
+1.41 (4.15%)
At close: Mar 10, 2026
Pharmaids Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 254.67 | 194.47 | 151.12 | - | 39.39 | 85.51 | Upgrade
|
| Other Revenue | 0.66 | 0.66 | 1.88 | - | - | - | Upgrade
|
| Revenue | 255.33 | 195.14 | 153 | - | 39.39 | 85.51 | Upgrade
|
| Revenue Growth (YoY) | -14.24% | 27.54% | - | - | -53.93% | - | Upgrade
|
| Cost of Revenue | 159.86 | 132.37 | 125.11 | 9.04 | 35.71 | 81.59 | Upgrade
|
| Gross Profit | 95.47 | 62.76 | 27.89 | -9.04 | 3.68 | 3.92 | Upgrade
|
| Selling, General & Admin | 159.65 | 144.25 | 97.01 | 13.06 | 0.67 | 0.83 | Upgrade
|
| Other Operating Expenses | 105.99 | 45.2 | 51.95 | 76.81 | 1.63 | 2.02 | Upgrade
|
| Operating Expenses | 287.35 | 213.85 | 166.22 | 90.04 | 2.4 | 3.3 | Upgrade
|
| Operating Income | -191.88 | -151.09 | -138.32 | -99.08 | 1.28 | 0.62 | Upgrade
|
| Interest Expense | -37.69 | -20.07 | -15.42 | - | - | - | Upgrade
|
| Interest & Investment Income | 0.29 | 0.29 | 0.28 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.14 | -0.14 | -0.45 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.79 | -0.8 | 6.2 | -0 | 0.12 | 0.26 | Upgrade
|
| EBT Excluding Unusual Items | -228.63 | -171.81 | -147.71 | -99.08 | 1.4 | 0.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.32 | - | - | - | Upgrade
|
| Other Unusual Items | 26.14 | -0.98 | -8.18 | - | - | - | Upgrade
|
| Pretax Income | -202.49 | -172.79 | -156.21 | -99.08 | 1.4 | 0.88 | Upgrade
|
| Income Tax Expense | -49.59 | -37.74 | -37.78 | -23.52 | -0.05 | -0.05 | Upgrade
|
| Earnings From Continuing Operations | -152.9 | -135.05 | -118.43 | -75.56 | 1.45 | 0.93 | Upgrade
|
| Minority Interest in Earnings | 14.43 | 27.29 | 38.75 | - | - | - | Upgrade
|
| Net Income | -138.47 | -107.77 | -79.68 | -75.56 | 1.45 | 0.93 | Upgrade
|
| Net Income to Common | -138.47 | -107.77 | -79.68 | -75.56 | 1.45 | 0.93 | Upgrade
|
| Net Income Growth | - | - | - | - | 55.55% | 178.26% | Upgrade
|
| Shares Outstanding (Basic) | 35 | 35 | 23 | 13 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 35 | 35 | 23 | 13 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | -53.92% | 55.24% | 76.16% | 25.07% | - | - | Upgrade
|
| EPS (Basic) | -3.91 | -3.06 | -3.51 | -5.86 | 0.14 | 0.09 | Upgrade
|
| EPS (Diluted) | -3.91 | -3.06 | -3.51 | -5.86 | 0.14 | 0.09 | Upgrade
|
| EPS Growth | - | - | - | - | 55.56% | 200.01% | Upgrade
|
| Free Cash Flow | - | -264.72 | -334.82 | -56.92 | -2.59 | 4.04 | Upgrade
|
| Free Cash Flow Per Share | - | -7.51 | -14.74 | -4.41 | -0.25 | 0.39 | Upgrade
|
| Gross Margin | 37.39% | 32.16% | 18.23% | - | 9.34% | 4.58% | Upgrade
|
| Operating Margin | -75.15% | -77.43% | -90.41% | - | 3.25% | 0.73% | Upgrade
|
| Profit Margin | -54.23% | -55.23% | -52.08% | - | 3.69% | 1.09% | Upgrade
|
| Free Cash Flow Margin | - | -135.66% | -218.84% | - | -6.58% | 4.72% | Upgrade
|
| EBITDA | -164.46 | -128.03 | -121.07 | -98.91 | 1.36 | 1.07 | Upgrade
|
| EBITDA Margin | -64.41% | -65.61% | -79.13% | - | 3.46% | 1.25% | Upgrade
|
| D&A For EBITDA | 27.42 | 23.06 | 17.25 | 0.17 | 0.08 | 0.45 | Upgrade
|
| EBIT | -191.88 | -151.09 | -138.32 | -99.08 | 1.28 | 0.62 | Upgrade
|
| EBIT Margin | -75.15% | -77.43% | -90.41% | - | 3.25% | 0.73% | Upgrade
|
| Revenue as Reported | 257.3 | 195.51 | 159.9 | - | 39.54 | 85.77 | Upgrade
|
| Advertising Expenses | - | 1.34 | 0.15 | 0 | 0.11 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.